John LambertAnavex Pre-Clinical Results for Parkinson’sThis past week, Anavex Life Sciences (AVXL) reported the summary results of the pre-clinical trials of Anavex 2–73 for Parkinson’s, and the…Sep 24, 2016Sep 24, 2016
John LambertBackgrounder on Epilepsy and Anavex Life SciencesAnavex Life Science’s leading drug candidate, Anavex 2–73, is now at the design stage for a pivotal phase 2/3 trial targeting Alzheimer’s…Nov 20, 20151Nov 20, 20151
John LambertThe Anavex Story for Honest InvestorsThis article is a rebuttal to one published yesterday purporting to tell the Anavex story. It doesn’t. It merely attacks Anavex with…Nov 10, 20158Nov 10, 20158